Startseite Measurement of amino terminal propeptide of type III procollagen (PIIINP) employing the ADVIA Centaur platform. Validation, reference interval and comparison to UniQ RIA
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Measurement of amino terminal propeptide of type III procollagen (PIIINP) employing the ADVIA Centaur platform. Validation, reference interval and comparison to UniQ RIA

  • Cindy Soendersoe Knudsen EMAIL logo , Lene Heickendorff und Ebba Nexo
Veröffentlicht/Copyright: 11. Oktober 2013
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Background: Recently, measurement of amino terminal propeptide of type III procollagen (PIIINP) was introduced as a part of the hepatic cirrhotic marker enhanced liver fibrosis™ test on the automated ADVIA Centaur® immunoassay platform (Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA). In this article, we show that the Centaur PIIINP may be used in place of the much more labor-intensive RIA method, and we present an age stratified reference interval.

Methods: We analyzed four control samples 20 times over a period of 5 days. Centaur PIIINP assay measurements were compared with the widely used UniQ PIIINP RIA assay (Orion Diagnostica, Espoo, Finland) using 55 patient samples (range=3.7–43.3 µg/L). Furthermore, we established a reference interval based on samples from 287 blood donors.

Results: In the concentration range 2.5–11.9 µg/L, the total imprecision was below 8%. Comparison with the UniQ PIIINP RIA assay yielded: Centaur PIIINP µg/L=1.9×(UniQ PIIINP RIA)+0.6 µg/L, r2=0.94. The reference interval for the Centaur PIIINP assay showed no gender difference but was stratified by age [4.0–11.0 µg/L (18–40 years) and 3.5–9.5 µg/L (41–70 years)].

Conclusions: We conclude that the Centaur PIIINP assay is suitable for routine use with our newly defined reference interval. The results obtained by Centaur correlates well with those obtained by the previously employed RIA, though the absolute values are higher.


Corresponding author: Cindy Soendersoe Knudsen, Department of Clinical Biochemistry, Aarhus University Hospital, Norrebrogade 44, 8000 Aarhus C, Denmark, Phone: +45-7846-3077, Fax: +45-7846-3060, E-mail:

Birgitte Høvsgaard is acknowledged for expert technical assistance and advice.

Conflict of interest statement

Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. The company donating the kits had no influence in the design of the study and did not participate in preparation of the manuscript.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

References

1. Zachariae H, Heickendorf L, Søgaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10 year follow-up. Br J Dermatol 2001;143:100–3.10.1046/j.1365-2133.2001.03959.xSuche in Google Scholar PubMed

2. Chalmers RJ, Kirby B, Smith A, Burrows P, Little R, Horan M, et al. Replacement of routine liver biopsy by collagen I aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005;152:444–50.10.1111/j.1365-2133.2005.06422.xSuche in Google Scholar PubMed

3. Maurice PD, Maddox AJ, Green CA, Tatnall F, Schofield JK, Stott DJ. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br J Dermatol 2005;152:451–8.10.1111/j.1365-2133.2005.06459.xSuche in Google Scholar PubMed

4. Barker J, Horn EJ, Lebwohl M, Warren RB, Nast A, Rosenberg W, et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol 2011;25:758–64.10.1111/j.1468-3083.2010.03932.xSuche in Google Scholar PubMed

5. Herrmann K, Schulze E, Heckmann M, Schubert I, Meurer M, Ziegler V, et al. Type III collagen aminopeptide and laminin P1 levels in serum of patients with silicosis-associated and idiopathic systemic scleroderma. Br J Dermatol 1990;123:1–7.10.1111/j.1365-2133.1990.tb01818.xSuche in Google Scholar PubMed

6. Guseva NG, Anikina NV, Myllyla R, Risteli L, Risteli J, Chochlova JV, et al. Markers of collagen and basement membrane metabolism in sera of patients with progressive systemic sclerosis. Ann Rheum Dis 1991;50:481–6.10.1136/ard.50.7.481Suche in Google Scholar PubMed PubMed Central

7. Lee YJ, Shin KC, Kang SW, Lee EB, Kim HA, Song YW. Type III procollagen N-terminal propeptide, soluble interleukin-2, and von Willebrand factor in systemic sclerosis. Clin Exp Rheumatol 2001;19:69–74.Suche in Google Scholar

8. Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, et al. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholoc steatohepatotis in patients with nonalcoholic fatty liver disease. Hepatology 2013;57:103–11.10.1002/hep.26030Suche in Google Scholar PubMed

9. Dixon WJ. Processing data for outliers. Biometrics 1953;9: 74–89.10.2307/3001634Suche in Google Scholar

10. Harris EK, Boyd JC. On dividing reference data into subgroups to produce separate reference ranges. Clin Chem 1990;36: 265–70.10.1093/clinchem/36.2.265Suche in Google Scholar

11. CLSI. Defining, Establishing, and verifying Reference Intervals in the Clinical Laboratory; Approved Guideline, 3rd ed. CLSI document C28-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.Suche in Google Scholar

12. Risteli J, Niemi S, Trivedi P, Mäentausta O, Mowat AP, Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem 1988;34:715–8.10.1093/clinchem/34.4.715Suche in Google Scholar

Received: 2013-7-15
Accepted: 2013-8-27
Published Online: 2013-10-11
Published in Print: 2014-2-1

©2014 by Walter de Gruyter Berlin Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. The ten commandments of laboratory testing for emergency physicians
  4. Review
  5. Critical role of RAGE in lung physiology and tumorigenesis: a potential target of therapeutic intervention?
  6. Opinion Papers
  7. Do we really need high-sensitive troponin immunoassays in the emergency department? Definitely, yes!
  8. Do we really need high-sensitivity troponin immunoassays in the emergency department? Maybe not
  9. General Clinical Chemistry and Laboratory Medicine
  10. Cortisol and cortisone ratio in urine: LC-MS/MS method validation and preliminary clinical application
  11. Urinary neutrophil gelatinase-associated lipocalin (NGAL) excretion increases in normal pregnancy but not in preeclampsia
  12. Influence of urine volume on the assessment of intestinal permeability in affected children by multiple sugar probes
  13. Measurement of amino terminal propeptide of type III procollagen (PIIINP) employing the ADVIA Centaur platform. Validation, reference interval and comparison to UniQ RIA
  14. Cancer Diagnostics
  15. Enrichment and enumeration of circulating tumor cells by efficient depletion of leukocyte fractions
  16. Immunological screening for tumor cells in serous body fluids has added value with the CELL-DYN Sapphire
  17. Cardiovascular Diseases
  18. The value of clinical and laboratory diagnostics for chest pain patients at the emergency department
  19. The concentration of high-sensitivity troponin I, galectin-3 and NT-proBNP substantially increase after a 60-km ultramarathon
  20. Autoantibody prevalence with an improved immunoassay for detecting cardiac troponin-specific autoantibodies
  21. Increased B-type natriuretic peptide levels in early-onset versus late-onset preeclampsia
  22. Association of the GCKR rs780094 polymorphism with metabolic traits including carotid intima-media thickness in Japanese community-dwelling men, but not in women
  23. Infectious Diseases
  24. Analysis of antibody response (IgM, IgG, IgG3) to Chikungunya virus using panel of peptides derived from envelope protein for serodiagnosis
  25. Letters to the Editor
  26. A short story on how the H-index may change the fate of scientists and scientific publishing
  27. A new and effective way for preventing pre-analytical laboratory errors
  28. Digital immunofluorescence enables automated detection of antinuclear antibody endpoint titers avoiding serial dilution
  29. Multicenter method evaluation of the ARK™ Methotrexate Immunoassay
  30. Haemoglobinopathies in nonendemic areas in recent years
  31. Clinical implications of a recent adjustment to the high-sensitivity cardiac troponin T assay: some results
  32. Effect of recalibration of the hs-TnT assay on diagnostic performance
Heruntergeladen am 14.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2013-0502/html
Button zum nach oben scrollen